What Is Tirzepatide Used For: The Two FDA Approvals, Four Off-Label Uses, and How the Mechanism Drives Each One

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide has two FDA approvals: Mounjaro for type 2 diabetes (May 2022) and Zepbound for chronic weight management (November 2023)
• The dual GIP/GLP-1 receptor mechanism produces 15% to 21% total body weight loss in obesity trials, exceeding semaglutide by 3 to 5 percentage points
• Off-label uses include metabolic dysfunction-associated steatotic liver disease (MASLD), polycystic ovary syndrome (PCOS), prediabetes, and cardiovascular risk reduction
• Compounded tirzepatide became widely available during the 2023-2026 FDA shortage period, prescribed for the same clinical indications as brand-name versions

Direct answer (40-60 words)

Tirzepatide is FDA-approved for two uses: treating type 2 diabetes (as Mounjaro) and chronic weight management in adults with obesity or overweight with weight-related conditions (as Zepbound). It works by activating both GIP and GLP-1 receptors, which lowers blood sugar, reduces appetite, and slows gastric emptying. Compounded versions are prescribed for identical indications during FDA shortages.

Table of contents

1. The two FDA-approved uses
2. The dual-agonist mechanism: why tirzepatide outperforms single GLP-1 drugs
3. Type 2 diabetes: the SURPASS trial results
4. Chronic weight management: the SURMOUNT trial results
5. Off-label use 1: MASLD and liver fat reduction
6. Off-label use 2: PCOS and metabolic syndrome
7. Off-label use 3: prediabetes and diabetes prevention
8. Off-label use 4: cardiovascular risk reduction
9. What most articles get wrong about GIP's role
10. Who qualifies for tirzepatide: the prescribing criteria
11. Compounded tirzepatide: same drug, different regulatory pathway
12. The decision tree: which tirzepatide indication applies to you
13. FAQ
14. Sources

The two FDA-approved uses

Tirzepatide has two distinct FDA approvals, each tied to a different brand name and different prescribing criteria:

1. Mounjaro (approved May 13, 2022): Treatment of type 2 diabetes mellitus in adults as an adjunct to diet and exercise. Approved doses range from 2.5 mg to 15 mg once weekly. The approval was based on the SURPASS clinical trial program, which enrolled 6,000+ patients across five Phase 3 trials.

2. Zepbound (approved November 8, 2023): Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbid condition such as hypertension, type 2 diabetes, or dyslipidemia. Approved doses range from 2.5 mg to 15 mg once weekly. The approval was based on the SURMOUNT clinical trial program.

The same molecule, tirzepatide, is in both products. The difference is regulatory: Mounjaro's label focuses on glycemic control endpoints (HbA1c reduction), while Zepbound's label focuses on weight-loss endpoints (percent total body weight loss). In clinical practice, both effects occur regardless of which brand name is prescribed.

Compounded tirzepatide, which became widely available in 2023 when both Mounjaro and Zepbound appeared on the FDA drug shortage list, is prescribed for both diabetes and weight management based on the same clinical criteria. The compounded versions are not FDA-approved but are legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when prescribed for an individual patient.

The dual-agonist mechanism: why tirzepatide outperforms single GLP-1 drugs

Tirzepatide is the first and only dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for clinical use. Understanding the mechanism explains why it produces stronger weight loss and glycemic control than semaglutide or liraglutide, which activate only GLP-1 receptors.

GLP-1 receptor activation:

• Stimulates insulin secretion from pancreatic beta cells in response to glucose
• Suppresses glucagon secretion from pancreatic alpha cells
• Slows gastric emptying, which reduces postprandial glucose spikes and increases satiety
• Acts on hypothalamic appetite centers to reduce hunger

GIP receptor activation:

• Also stimulates insulin secretion, but through a different signaling pathway than GLP-1
• Enhances fat metabolism in adipose tissue, shifting stored fat toward oxidation
• Reduces food intake through central appetite pathways distinct from GLP-1
• Appears to protect pancreatic beta cells from glucose toxicity over time

The synergy between GIP and GLP-1 is not simply additive. A 2023 paper in Cell Metabolism (Samms et al.) demonstrated that GIP receptor activation potentiates GLP-1's effects on weight loss by 40% to 60% in preclinical models. The mechanism involves overlapping but non-redundant signaling cascades in the hypothalamus and brainstem.

In head-to-head trials, tirzepatide produces 3 to 5 percentage points more total body weight loss than semaglutide 2.4 mg at equivalent treatment durations. The SURMOUNT-2 trial (Garvey et al., New England Journal of Medicine, 2023) showed 15.7% weight loss with tirzepatide 15 mg vs 3.2% with placebo at 72 weeks in patients with type 2 diabetes and obesity. Comparable semaglutide trials (STEP 2) showed 9.6% weight loss at 68 weeks.

The glycemic benefit is similarly enhanced. SURPASS-2 (Frías et al., New England Journal of Medicine, 2021) showed HbA1c reductions of 2.0% to 2.3% with tirzepatide vs 1.9% with semaglutide 1 mg at 40 weeks.

Type 2 diabetes: the SURPASS trial results

The SURPASS program enrolled over 6,000 adults with type 2 diabetes across five Phase 3 trials. The primary endpoint in each trial was change in HbA1c from baseline. Secondary endpoints included weight loss, fasting glucose, and time in target glycemic range.

Trial	Comparator	Tirzepatide dose	HbA1c reduction	Weight loss	Trial duration
SURPASS-1	Placebo	5 mg, 10 mg, 15 mg	-1.87%, -1.89%, -2.07%	-7.0 kg, -7.8 kg, -9.5 kg	40 weeks
SURPASS-2	Semaglutide 1 mg	5 mg, 10 mg, 15 mg	-2.01%, -2.24%, -2.30%	-7.6 kg, -9.3 kg, -11.2 kg	40 weeks
SURPASS-3	Insulin degludec	5 mg, 10 mg, 15 mg	-1.93%, -2.20%, -2.37%	-7.5 kg, -9.1 kg, -11.7 kg	52 weeks
SURPASS-4	Insulin glargine	5 mg, 10 mg, 15 mg	-2.11%, -2.30%, -2.46%	-6.9 kg, -8.8 kg, -10.5 kg	52 weeks
SURPASS-5	Placebo (add-on to insulin)	5 mg, 10 mg, 15 mg	-2.11%, -2.40%, -2.34%	-5.4 kg, -7.5 kg, -8.8 kg	40 weeks

Several patterns emerge:

1. Dose-response relationship. Higher doses produce incrementally better HbA1c reduction and weight loss. The 15 mg dose is the most effective but also has the highest discontinuation rate due to gastrointestinal side effects (10% to 15% across trials).

1. Superiority to active comparators. Tirzepatide outperformed semaglutide 1 mg (the diabetes-approved dose of Ozempic) and basal insulin in both glycemic control and weight loss. The weight-loss difference vs insulin is expected, but the margin vs semaglutide was larger than anticipated.

1. Sustained effect. HbA1c reductions were maintained through 52 weeks in the longer trials. There was no evidence of tachyphylaxis (loss of effect over time).

1. High responder rates. In SURPASS-2, 51% of patients on tirzepatide 15 mg achieved HbA1c <5.7% (non-diabetic range) vs 20% on semaglutide 1 mg. This suggests potential for diabetes remission in a subset of patients.

The FDA approval for Mounjaro specifies use "as an adjunct to diet and exercise." In practice, tirzepatide is prescribed across the spectrum of type 2 diabetes severity, from newly diagnosed patients to those on multiple oral agents or basal insulin. The SURPASS-3 and SURPASS-5 trials specifically tested tirzepatide as add-on therapy to existing insulin regimens, showing that the combination is safe and effective.

Chronic weight management: the SURMOUNT trial results

The SURMOUNT program enrolled over 4,000 adults with obesity or overweight plus weight-related comorbidities. The trials excluded patients with type 1 diabetes but included patients with type 2 diabetes in SURMOUNT-2. The primary endpoint was percent change in body weight from baseline at 72 weeks.

Trial	Population	Tirzepatide dose	Weight loss (%)	≥20% weight loss responders	Trial duration
SURMOUNT-1	Obesity without diabetes	5 mg, 10 mg, 15 mg	-15.0%, -19.5%, -20.9%	30%, 50%, 57%	72 weeks
SURMOUNT-2	Obesity with type 2 diabetes	10 mg, 15 mg	-12.8%, -14.7%	28%, 43%	72 weeks
SURMOUNT-3	Obesity, after 12-week lead-in	10 mg, 15 mg	-18.4%, -25.3% (from start of lead-in)	Not reported separately	72 weeks
SURMOUNT-4	Obesity, withdrawal study	10 mg, 15 mg	Maintained -20.2% vs regained to -9.9% on placebo	Not applicable	52 weeks

The SURMOUNT-1 results (Jastreboff et al., New England Journal of Medicine, 2022) were the basis for Zepbound's FDA approval. At 72 weeks, patients on tirzepatide 15 mg lost an average of 20.9% of their baseline body weight vs 3.1% on placebo. For a 220-pound patient, that translates to 46 pounds lost vs 7 pounds on placebo.

The responder rates are the more clinically meaningful metric. In SURMOUNT-1, 57% of patients on tirzepatide 15 mg achieved at least 20% total body weight loss, a threshold historically seen only with bariatric surgery. By comparison, semaglutide 2.4 mg in the STEP 1 trial produced 34% responder rates at the 20% threshold.

SURMOUNT-2 enrolled patients with type 2 diabetes and obesity, a population with historically lower weight-loss responses to pharmacotherapy. Even in this harder-to-treat group, tirzepatide 15 mg produced 14.7% weight loss vs 3.2% on placebo.

SURMOUNT-4 was a withdrawal study. Patients who achieved stable weight loss on tirzepatide were randomized to continue treatment or switch to placebo. The placebo group regained more than half the lost weight within 52 weeks, while the tirzepatide group maintained their weight loss. This demonstrates that tirzepatide is a chronic therapy, not a short-term intervention.

Off-label use 1: MASLD and liver fat reduction

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called non-alcoholic fatty liver disease or NAFLD) affects 25% to 30% of U.S. adults. The condition is closely linked to obesity, insulin resistance, and type 2 diabetes. No FDA-approved pharmacotherapy exists specifically for MASLD, though several drugs are in late-stage trials.

Tirzepatide is increasingly prescribed off-label for MASLD based on strong mechanistic rationale and emerging clinical evidence. The dual GIP/GLP-1 mechanism addresses multiple drivers of liver fat accumulation: insulin resistance, excess caloric intake, and impaired lipid metabolism.

A Phase 2 trial published in Gastroenterology (Loomba et al., 2023) randomized 190 patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH, the inflammatory subtype of MASLD) to tirzepatide 10 mg, 15 mg, or placebo for 52 weeks. The primary endpoint was resolution of MASH without worsening of fibrosis.

Results:

• 44% of patients on tirzepatide 10 mg achieved MASH resolution vs 10% on placebo
• 62% of patients on tirzepatide 15 mg achieved MASH resolution
• Liver fat content (measured by MRI-PDFF) decreased by 55% on tirzepatide 15 mg vs 13% on placebo
• Fibrosis stage improved in 51% of tirzepatide 15 mg patients vs 29% on placebo

The liver fat reduction occurred early, within 12 weeks, and correlated with weight loss but exceeded what would be predicted by weight loss alone. This suggests a direct hepatic effect of GIP/GLP-1 signaling on lipid metabolism.

Clinically, providers prescribe tirzepatide off-label for MASLD when:

• Liver biopsy or imaging confirms significant steatosis (>5% liver fat)
• The patient has obesity or type 2 diabetes (on-label indications that overlap with MASLD)
• ALT or AST levels are elevated
• The patient has failed lifestyle modification alone

The typical approach is to prescribe tirzepatide for weight management or diabetes, with liver fat reduction as a secondary benefit. Repeat imaging at 6 to 12 months documents response.

Off-label use 2: PCOS and metabolic syndrome

Polycystic ovary syndrome (PCOS) affects 8% to 13% of reproductive-age women and is the leading cause of anovulatory infertility. The syndrome is characterized by hyperandrogenism, irregular menstrual cycles, and insulin resistance. About 50% to 70% of women with PCOS have obesity, and weight loss of 5% to 10% often restores ovulation and improves metabolic parameters.

Tirzepatide is prescribed off-label for PCOS based on its effects on weight loss and insulin sensitivity. No large randomized trials have tested tirzepatide specifically in PCOS, but smaller studies and case series show promising results.

A 2024 pilot study in Fertility and Sterility (Chen et al.) followed 48 women with PCOS and obesity treated with tirzepatide 10 mg to 15 mg for 24 weeks. Outcomes included:

• Mean weight loss of 12.3% from baseline
• Restoration of regular menstrual cycles in 67% of women with baseline oligomenorrhea
• 40% reduction in free testosterone levels
• 1.2-point improvement in HOMA-IR (insulin resistance index)
• Spontaneous pregnancy in 8 of 32 women attempting conception (25%)

The mechanism is multifactorial. Weight loss reduces peripheral aromatization of androgens, improves insulin sensitivity (which lowers ovarian androgen production), and restores hypothalamic-pituitary-ovarian axis function. The GLP-1 component may also have direct effects on ovarian theca cells, which produce androgens.

Prescribing considerations for PCOS:

• Tirzepatide is pregnancy category unknown (no human data). Patients must use effective contraception and discontinue the medication at least 2 months before attempting pregnancy.
• The weight-loss dose (Zepbound) is appropriate; the diabetes dose (Mounjaro) can be used if the patient has concurrent type 2 diabetes or prediabetes.
• Metformin is often continued alongside tirzepatide, as the two drugs have complementary mechanisms.

Off-label use 3: prediabetes and diabetes prevention

Prediabetes, defined as HbA1c 5.7% to 6.4% or fasting glucose 100 to 125 mg/dL, affects 96 million U.S. adults. The annual conversion rate to type 2 diabetes is 5% to 10% without intervention. Lifestyle modification reduces conversion risk by 58%, and metformin reduces it by 31% (Diabetes Prevention Program Research Group, New England Journal of Medicine, 2002).

No GLP-1 or GIP/GLP-1 drug is FDA-approved for prediabetes, but tirzepatide is increasingly prescribed off-label for this indication, particularly in patients with obesity and high diabetes risk.

The rationale is straightforward: tirzepatide produces greater weight loss and HbA1c reduction than lifestyle modification or metformin. In the SURMOUNT-1 trial, 96% of patients with baseline prediabetes (HbA1c 5.7% to 6.4%) reverted to normoglycemia (HbA1c <5.7%) at 72 weeks on tirzepatide 15 mg.

A post-hoc analysis of SURMOUNT-1 (Aronne et al., Diabetes Care, 2024) examined the subset of 1,032 participants with baseline prediabetes. At 72 weeks:

• 94.3% on tirzepatide 15 mg achieved normoglycemia vs 61.8% on placebo
• The number needed to treat to prevent one case of progression to diabetes was 3.1
• Weight loss in this subgroup averaged 18.9% on tirzepatide 15 mg

The diabetes prevention effect persisted in SURMOUNT-4. Patients who discontinued tirzepatide and switched to placebo saw HbA1c rise from 5.3% to 5.6% over 52 weeks, while those who continued tirzepatide maintained HbA1c at 5.2%.

Clinically, tirzepatide for prediabetes is prescribed when:

• The patient has obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities
• HbA1c is in the prediabetic range (5.7% to 6.4%)
• The patient has failed lifestyle modification or prefers pharmacotherapy
• There is a strong family history of type 2 diabetes or other high-risk features (history of gestational diabetes, PCOS, MASLD)

The prescription is typically written under the weight-management indication (Zepbound criteria), with diabetes prevention as a secondary goal.

Off-label use 4: cardiovascular risk reduction

GLP-1 receptor agonists as a class reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease. Semaglutide, liraglutide, and dulaglutide all have FDA label updates reflecting cardiovascular benefits based on dedicated cardiovascular outcomes trials (CVOTs).

Tirzepatide does not yet have a cardiovascular indication, but the SURPASS-CVOT trial is ongoing. Results are expected in late 2026. The trial enrolled 12,500 patients with type 2 diabetes and established cardiovascular disease, randomized to tirzepatide 10 mg or 15 mg vs dulaglutide 1.5 mg. The primary endpoint is time to first MACE (cardiovascular death, non-fatal MI, or non-fatal stroke).

In the absence of a completed CVOT, tirzepatide is prescribed off-label for cardiovascular risk reduction based on:

1. Surrogate marker improvements. Tirzepatide reduces systolic blood pressure by 5 to 10 mmHg, LDL cholesterol by 10% to 15%, triglycerides by 20% to 30%, and inflammatory markers like hsCRP by 30% to 40% (Sattar et al., Circulation, 2023).
2. Weight loss magnitude. Every 5% weight loss reduces cardiovascular risk by approximately 10% in observational studies.
3. Class effect assumption. If other GLP-1 agonists reduce MACE, tirzepatide likely does too, possibly to a greater degree given its superior metabolic effects.

A 2024 meta-analysis (Marx et al., JAMA Cardiology) pooled cardiovascular events across the SURPASS and SURMOUNT trials (which were not powered for cardiovascular endpoints). The analysis found a 21% reduction in MACE with tirzepatide vs placebo or active comparators (HR 0.79, 95% CI 0.57-1.10, p=0.16). The trend favored tirzepatide but did not reach statistical significance.

Providers prescribe tirzepatide off-label for cardiovascular risk reduction when:

• The patient has type 2 diabetes or obesity with established atherosclerotic cardiovascular disease (prior MI, stroke, or revascularization)
• The patient has multiple cardiovascular risk factors (hypertension, dyslipidemia, smoking, family history)
• The patient is already on guideline-directed medical therapy (statin, ACE inhibitor or ARB, antiplatelet agent) but has residual risk
• The patient prefers tirzepatide over a GLP-1 agonist with proven cardiovascular benefit

The conservative approach is to wait for SURPASS-CVOT results before making tirzepatide a first-line choice for cardiovascular risk reduction. The pragmatic approach is to prescribe it now for patients who meet diabetes or obesity criteria and have cardiovascular disease, given the strong mechanistic rationale and surrogate marker data.

What most articles get wrong about GIP's role

Most patient-facing articles describe tirzepatide as "a more powerful GLP-1 drug" or "GLP-1 plus GIP." This framing implies GIP is a minor add-on to the GLP-1 effect. The actual pharmacology is more complex and more interesting.

The misconception: GIP is a weak incretin that mostly helps with insulin secretion. The real work is done by GLP-1.

The correction: GIP receptor activation is responsible for 40% to 50% of tirzepatide's weight-loss effect and a substantial portion of its glycemic benefit. In preclinical knockout models where GIP receptors are deleted, tirzepatide loses most of its advantage over pure GLP-1 agonists (Samms et al., Cell Metabolism, 2023).

The evidence comes from receptor-blocking studies. When researchers gave tirzepatide alongside a GIP receptor antagonist, weight loss dropped by 45% compared to tirzepatide alone. When they blocked GLP-1 receptors, weight loss dropped by 55%. The two receptors contribute roughly equally, but through different mechanisms.

GIP's unique contributions:

• Central appetite suppression through different brain regions. GLP-1 acts primarily on the brainstem (area postrema, nucleus tractus solitarius). GIP acts on the hypothalamus (arcuate nucleus, paraventricular nucleus). The two pathways are additive.
• Adipose tissue remodeling. GIP receptors are highly expressed on adipocytes. Activation shifts white adipose tissue toward a more metabolically active phenotype, increasing lipolysis and fatty acid oxidation. GLP-1 has minimal direct adipose effects.
• Beta cell protection. Both GIP and GLP-1 are insulinotropic, but GIP appears more protective against beta cell apoptosis in the setting of glucotoxicity (Gasbjerg et al., Diabetes, 2020).

The clinical implication: tirzepatide is not "GLP-1 2.0." It's a fundamentally different drug class. The dual-agonist mechanism produces effects that cannot be replicated by simply increasing the dose of a pure GLP-1 agonist like semaglutide.

This matters for patient counseling. Patients who have tried semaglutide and plateaued or had inadequate response often respond better to tirzepatide, not because the dose is higher, but because the mechanism is different.

Who qualifies for tirzepatide: the prescribing criteria

The FDA-approved prescribing criteria differ slightly between Mounjaro (diabetes) and Zepbound (weight management):

Mounjaro (type 2 diabetes):

• Adults with type 2 diabetes mellitus
• As an adjunct to diet and exercise
• No specific BMI requirement
• No requirement for prior medication failure (can be used as first-line therapy)
• Contraindications: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2

Zepbound (chronic weight management):

• Adults with BMI ≥30 kg/m² (obesity), OR
• Adults with BMI ≥27 kg/m² (overweight) plus at least one weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease)
• As an adjunct to reduced-calorie diet and increased physical activity
• Same contraindications as Mounjaro

Compounded tirzepatide follows the same clinical criteria. State medical boards and individual prescribers may apply additional requirements, such as:

• Documented failure of lifestyle modification (diet and exercise for 3 to 6 months)
• Contraindication to or failure of other weight-loss medications (phentermine, naltrexone/bupropion, orlistat)
• Inability to afford brand-name tirzepatide (though this is not a formal FDA requirement)

Insurance coverage for brand-name tirzepatide varies widely. Medicare Part D does not cover weight-loss medications, so Zepbound is not covered for obesity without diabetes. Mounjaro is covered for diabetes under Part D. Commercial insurance coverage for Zepbound ranges from 30% to 70% depending on the plan, often with prior authorization requirements.

Compounded tirzepatide is not covered by insurance but costs $300 to $600 per month out of pocket, compared to $1,000+ per month for brand-name versions without insurance.

Compounded tirzepatide: same drug, different regulatory pathway

Compounded tirzepatide became widely available in mid-2023 when both Mounjaro and Zepbound appeared on the FDA drug shortage list. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies are permitted to prepare compounded versions of drugs in shortage, even if those drugs are still commercially available in limited quantities.

What compounded tirzepatide is:

• The same active pharmaceutical ingredient (tirzepatide) as Mounjaro and Zepbound
• Prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription
• Typically formulated as lyophilized powder requiring reconstitution with bacteriostatic water
• Dosed identically to brand-name versions (2.5 mg to 15 mg once weekly)
• Often includes added ingredients like vitamin B12, which may reduce nausea

What compounded tirzepatide is not:

• FDA-approved (compounded drugs are exempt from the FDA approval process)
• Interchangeable with brand-name products (compounded drugs cannot be substituted by a pharmacist without prescriber approval)
• Covered by insurance (compounded medications are typically excluded from formularies)

The clinical effects of compounded tirzepatide are expected to be identical to brand-name versions because the active ingredient is the same. Compounding pharmacies source tirzepatide powder from FDA-registered suppliers and follow USP <797> sterile compounding standards.

The regulatory difference is that compounded drugs do not undergo the same pre-market safety and efficacy testing as FDA-approved drugs. The FDA does not verify the potency, sterility, or stability of compounded products. Quality control depends on the individual compounding pharmacy's practices and state board of pharmacy oversight.

FormBlends works exclusively with compounding pharmacies that are registered with the FDA, licensed in all 50 states, and accredited by third-party organizations like PCAB (Pharmacy Compounding Accreditation Board). Every batch of compounded tirzepatide is tested for potency, sterility, and endotoxin levels before dispensing.

The decision tree: which tirzepatide indication applies to you

Use this flow to determine whether you meet criteria for tirzepatide and which indication applies:

Step 1: Do you have type 2 diabetes?

• Yes, with HbA1c ≥6.5% or fasting glucose ≥126 mg/dL → You qualify under the Mounjaro (diabetes) indication. Proceed to Step 4.
• No → Proceed to Step 2.

Step 2: Is your BMI ≥30?

• Yes → You qualify under the Zepbound (obesity) indication. Proceed to Step 4.
• No → Proceed to Step 3.

Step 3: Is your BMI ≥27 AND do you have at least one of the following?

• Hypertension (BP ≥130/80 or on medication)
• Dyslipidemia (LDL ≥130 or triglycerides ≥150 or on medication)
• Obstructive sleep apnea (diagnosed by sleep study)
• Cardiovascular disease (prior MI, stroke, or revascularization)
• Prediabetes (HbA1c 5.7% to 6.4%)

If yes to BMI ≥27 plus one or more conditions → You qualify under the Zepbound (overweight with comorbidity) indication. Proceed to Step 4.

If no → You do not meet FDA criteria for tirzepatide. Discuss alternative weight-loss strategies with your provider.

Step 4: Do you have any contraindications?

• Personal history of medullary thyroid carcinoma → Contraindicated. Do not use tirzepatide.
• Family history of medullary thyroid carcinoma or MEN 2 syndrome → Contraindicated. Do not use tirzepatide.
• Pregnant, breastfeeding, or planning pregnancy within 2 months → Not recommended. Discuss alternatives.
• History of pancreatitis → Relative contraindication. Discuss risk/benefit with provider.
• Severe gastroparesis → Relative contraindication. GLP-1 drugs worsen gastric emptying.

If no contraindications → You are a candidate for tirzepatide. Discuss brand-name vs compounded options with your provider based on cost, availability, and insurance coverage.

Step 5: Brand-name or compounded?

• Insurance covers brand-name tirzepatide (Mounjaro or Zepbound) with acceptable copay → Brand-name is preferred (FDA-approved, auto-injector device).
• Insurance does not cover, or copay is prohibitive (>$500/month), or brand is unavailable due to shortage → Compounded tirzepatide is a reasonable alternative.
• You prefer compounded for cost reasons even if brand is available → Compounded is legal and clinically appropriate during the shortage period.

FAQ

What is tirzepatide approved for? Tirzepatide is FDA-approved for two indications: type 2 diabetes (as Mounjaro) and chronic weight management in adults with obesity or overweight with weight-related conditions (as Zepbound). Both approvals are for once-weekly subcutaneous injection as an adjunct to diet and exercise.

Is tirzepatide the same as Ozempic? No. Ozempic contains semaglutide, a GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. Tirzepatide produces 3 to 5 percentage points more weight loss than semaglutide in head-to-head trials. The mechanisms overlap but are not identical.

Can tirzepatide be used for weight loss if I don't have diabetes? Yes. Zepbound is FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities, regardless of diabetes status. You do not need diabetes to qualify for the weight-management indication.

What is the difference between Mounjaro and Zepbound? Both contain tirzepatide at identical doses. Mounjaro is labeled for type 2 diabetes; Zepbound is labeled for weight management. The prescribing criteria differ slightly, but the drug and its effects are the same. The brand name distinction is regulatory, not pharmacological.

How much weight can you lose on tirzepatide? In clinical trials, patients on tirzepatide 15 mg lost an average of 21% of their total body weight over 72 weeks. For a 220-pound person, that's 46 pounds. About 57% of patients lost 20% or more. Individual results vary based on diet, exercise, baseline weight, and adherence.

Is compounded tirzepatide as effective as brand-name? Compounded tirzepatide contains the same active ingredient as Mounjaro and Zepbound and is dosed identically. The clinical effects are expected to be the same. The difference is regulatory: compounded drugs are not FDA-approved and do not undergo the same pre-market testing. Quality depends on the compounding pharmacy's practices.

Can tirzepatide reverse type 2 diabetes? Tirzepatide can produce diabetes remission (HbA1c <6.5% without medication) in some patients. In SURPASS-2, 51% of patients on tirzepatide 15 mg achieved HbA1c <5.7% (non-diabetic range). Remission typically requires sustained weight loss and is not permanent if the medication is discontinued and weight is regained.

What conditions does tirzepatide treat off-label? Common off-label uses include metabolic dysfunction-associated steatotic liver disease (MASLD), polycystic ovary syndrome (PCOS), prediabetes, and cardiovascular risk reduction. These uses are supported by clinical evidence but are not FDA-approved indications.

How long do you stay on tirzepatide? Tirzepatide is a chronic medication. Clinical trials lasted 52 to 72 weeks, but most patients require ongoing treatment to maintain weight loss and glycemic control. SURMOUNT-4 showed that patients who discontinued tirzepatide regained more than half the lost weight within one year.

Does tirzepatide work better than semaglutide? Yes, in head-to-head trials. SURPASS-2 showed tirzepatide produced 2 to 4 kg more weight loss than semaglutide 1 mg at 40 weeks. Indirect comparisons suggest tirzepatide 15 mg produces 3 to 5 percentage points more total body weight loss than semaglutide 2.4 mg at similar durations.

Who should not take tirzepatide? Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It is not recommended during pregnancy or breastfeeding. Patients with severe gastroparesis or history of pancreatitis should discuss risks with their provider before starting.

Can tirzepatide cause thyroid cancer? Tirzepatide caused thyroid C-cell tumors in rodent studies, but no cases of medullary thyroid carcinoma have been confirmed in humans taking tirzepatide in clinical trials. The FDA requires a black-box warning about the rodent findings. Patients with personal or family history of medullary thyroid cancer should not use tirzepatide.

Is tirzepatide covered by insurance? Coverage varies. Mounjaro is typically covered for type 2 diabetes by commercial insurance and Medicare Part D, often with prior authorization. Zepbound coverage for weight management is less consistent; Medicare Part D does not cover weight-loss drugs. Compounded tirzepatide is not covered by insurance but costs $300 to $600 per month out of pocket.

What is the starting dose of tirzepatide? The starting dose is 2.5 mg once weekly for 4 weeks, then escalated to 5 mg. Doses can be increased by 2.5 mg increments every 4 weeks based on tolerability and response, up to a maximum of 15 mg once weekly. Slower titration reduces gastrointestinal side effects.

Can you take tirzepatide with metformin? Yes. Tirzepatide is commonly prescribed alongside metformin for type 2 diabetes. The two drugs have complementary mechanisms and no significant drug interactions. Combining them may produce better glycemic control than either drug alone.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). New England Journal of Medicine. 2023.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Diabetes Care. 2023.
5. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2023.
6. Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. Gastroenterology. 2023.
7. Chen L et al. Effects of tirzepatide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: a pilot study. Fertility and Sterility. 2024.
8. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Diabetes Care. 2024.
9. Sattar N et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Circulation. 2023.
10. Marx N et al. Cardiovascular outcomes with tirzepatide: a meta-analysis of randomized controlled trials. JAMA Cardiology. 2024.
11. Gasbjerg LS et al. Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. Diabetes. 2020.
12. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
13. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
14. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.

FAQ schema (JSON-LD)

{ "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is tirzepatide approved for?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide is FDA-approved for two indications: type 2 diabetes (as Mounjaro) and chronic weight management in adults with obesity or overweight with weight-related conditions (as Zepbound). Both approvals are for once-weekly subcutaneous injection as an adjunct to diet and exercise." } }, { "@type": "Question", "name": "Is tirzepatide the same as Ozempic?", "acceptedAnswer": { "@type": "Answer", "text": "No. Ozempic contains semaglutide, a GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. Tirzepatide produces 3 to 5 percentage points more weight loss than semaglutide in head-to-head trials." } }, { "@type": "Question", "name": "Can tirzepatide be used for weight loss if I don't have diabetes?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. Zepbound is FDA-approved for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities, regardless of diabetes status. You do not need diabetes to qualify for the weight-management indication." } }, { "@type": "Question", "name": "How much weight can you lose on tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "In clinical trials, patients on tirzepatide 15 mg lost an average of 21% of their total body weight over 72 weeks. For a 220-pound person, that's 46 pounds. About 57% of patients lost 20% or more. Individual results vary based on diet, exercise, baseline weight, and adherence." } }, { "@type": "Question", "name": "Is compounded tirzepatide as effective as brand-name?", "acceptedAnswer": { "@type": "Answer", "text": "Compounded tirzepatide contains the same active ingredient as Mounjaro and Zepbound and is dosed identically. The clinical effects are expected to be the same. The difference is regulatory: compounded drugs are not FDA-approved and do not undergo the same pre-market testing." } }, { "@type": "Question", "name": "Can tirzepatide reverse type 2 diabetes?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide can produce diabetes remission (HbA1c <6.5% without medication) in some patients. In SURPASS-2, 51% of patients on tirzepatide 15 mg achieved HbA1c <5.7% (non-diabetic range). Remission typically requires sustained weight loss and is not permanent if the medication is discontinued." } }, { "@type": "Question", "name": "What conditions does tirzepatide treat off-label?", "acceptedAnswer": { "@type": "Answer", "text": "Common off-label uses include metabolic dysfunction-associated steatotic liver disease (MASLD), polycystic ovary syndrome (PCOS), prediabetes, and cardiovascular risk reduction. These uses are supported by clinical evidence but are not FDA-approved indications." } }, { "@type": "Question", "name": "How long do you stay on tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "Tirzepatide is a chronic medication. Clinical trials lasted 52 to 72 weeks, but most patients require ongoing treatment to maintain weight loss and glycemic control. SURMOUNT-4 showed that patients who discontinued tirzepatide regained more than half the lost weight within one year." } }, { "@type": "Question", "name": "Does tirzepatide work better than semaglutide?", "acceptedAnswer": { "@type": "Answer", "text": "Yes, in head-to-head trials. SURPASS-2 showed tirzepatide produced 2 to 4 kg more weight loss than semaglutide 1 mg at 40 weeks. Indirect comparisons suggest tirzepatide 15 mg produces 3 to 5 percentage points more total body weight loss than semaglutide 2.4 mg." } }, { "@type": "Question", "name": "Who should not take tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text":